Capital Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Key Points

• Capital Investment Advisors LLC increased its stake in Gilead Sciences by 1.5%, now owning 358,139 shares valued at approximately $39.7 million.
• Gilead Sciences reported earnings of $2.01 per share for the last quarter, surpassing analyst expectations and achieving a revenue of $7.08 billion.
• The company recently declared a quarterly dividend of $0.79, with a yield of 2.8% and a payout ratio of 62.95%.

Capital Investment Advisors LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 358,139 shares of the biopharmaceutical company's stock after acquiring an additional 5,133 shares during the period. Capital Investment Advisors LLC's holdings in Gilead Sciences were worth $39,707,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Ariel Investments LLC grew its stake in shares of Gilead Sciences by 7.7% in the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after buying an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC grew its stake in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock worth $97,000 after buying an additional 109 shares during the last quarter. Swedbank AB grew its stake in shares of Gilead Sciences by 0.8% in the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company's stock worth $237,393,000 after buying an additional 16,663 shares during the last quarter. Covea Finance lifted its position in Gilead Sciences by 69.5% in the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company's stock valued at $5,732,000 after acquiring an additional 21,200 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in Gilead Sciences by 21.2% in the 1st quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company's stock valued at $15,986,000 after acquiring an additional 24,930 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 0.5%

Shares of Gilead Sciences stock opened at $112.62 on Tuesday. The firm has a market cap of $139.74 billion, a price-to-earnings ratio of 22.43, a PEG ratio of 0.76 and a beta of 0.36. The business has a 50-day moving average price of $114.50 and a 200-day moving average price of $109.90. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $82.82 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a research report on Tuesday, August 19th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Finally, Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $117.17.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares of the company's stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 72,000 shares of company stock worth $8,285,530 in the last 90 days. 0.27% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.